```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11   KOREAPAT updates resume
 NEWS  7  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  9  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 11  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 12  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14   FSTA enhanced with Japanese patents
 NEWS 15  JUl 19   Coverage of Research Disclosure reinstated in DWPI

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:23:06 ON 02 AUG 2006

=>
=> file medline, uspatful, biosis, wpids
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.46       5.46
```

FILE 'MEDLINE' ENTERED AT 10:38:25 ON 02 AUG 2006

FILE 'USPATFULL' ENTERED AT 10:38:25 ON 02 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:38:25 ON 02 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'WPIDS' ENTERED AT 10:38:25 ON 02 AUG 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s LDL particle
L1 1862 LDL PARTICLE

=> s Apo B
L2 9562 APO B

=> s l2 and (binding site)
L3 496 L2 AND (BINDING SITE)

=> s l3 and l1
L4 25 L3 AND L1

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 25 USPATFULL on STN
TI Novel composition
AB The present invention relates to novel therapies and treatments of atherosclerotic diseases. Accordingly there is provided, methods of treating or preventing atherosclerosis by passive vaccination through administration to a patient of a fully human antibody that is capable of binding to the specific fragments of ApoCIII. Specific human monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the antibodies of the present invention in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2005:330162 USPATFULL		
TITLE:	Novel composition		
INVENTOR(S):	Dhaese, Patrick, Rixensart, BELGIUM Mettens, Pascal, Rixensart, BELGIUM Meykens, Rene, Rixensart, BELGIUM Monteyne, Philippe, Rixensart, BELGIUM Schiott, Torbjorn, Lund, SWEDEN Strandberg, Leif, Lund, SWEDEN		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005287137	A1	20051229
APPLICATION INFO.:	US 2005-167872	A1	20050627 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-387955, filed on 15 Jul 2003, ABANDONED		
	NUMBER	DATE	
PRIORITY INFORMATION:	WO 2002-EP9650	20020829	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939, US		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		

LINE COUNT: 1047
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 25 USPATFULL on STN
TI Compositions and methods for treatment of neoplastic disease
AB The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides or nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are T cells and NKT cells activated by the above compositions that can be administered for adoptive immunotherapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:130682 USPATFULL
TITLE: Compositions and methods for treatment of neoplastic disease
INVENTOR(S): Terman, David S., Pebble Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005112141	A1	20050526
APPLICATION INFO.:	US 2004-937758	A1	20040908 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-650884, filed on 30 Aug 2000, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CENTRAL COAST PATENT AGENCY, PO BOX 187, AROMAS, CA, 95004, US
NUMBER OF CLAIMS: 81
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 12424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 25 USPATFULL on STN
TI Lipoproteins as nucleic acid vectors
AB The present invention relates to a composition and method for activating an antigen specific immune response using by providing a host with a native low density lipoprotein and a nucleic acid that expressed an antigen bound to the low density lipoprotein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:112203 USPATFULL
TITLE: Lipoproteins as nucleic acid vectors
INVENTOR(S): Guevara, Juan G. JR., Brownsville, TX, UNITED STATES
PATENT ASSIGNEE(S): Aragene, Inc., Houston, TX, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005096288	A1	20050505
APPLICATION INFO.:	US 2004-895250	A1	20040720 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-874807, filed on 13 Jun 1997, ABANDONED Continuation-in-part of Ser. No. US 1998-79030, filed on 14 May 1998, GRANTED, Pat.

No. US 6635623 Continuation-in-part of Ser. No. US 2003-656053, filed on 5 Sep 2003, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edwin Flores, Chalker Flores, LLP, 12700 Park Central Drive, Suite 455, Dallas, TX, 75251, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2586
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 25 USPATFULL on STN
TI Non-naturally occurring lipoprotein particle
AB Non-naturally occurring lipoprotein particles, process for preparing such particles and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:299861 USPATFULL
TITLE: Non-naturally occurring lipoprotein particle
INVENTOR(S): Halbert, Gavin William, Jordanhill, UNITED KINGDOM
Owens, Moira Doreen, Basel, SWITZERLAND
Baillie, George, Lochwinnoch, UNITED KINGDOM
PATENT ASSIGNEE(S): University of Strathclyde (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004235730	A1	20041125
APPLICATION INFO.:	US 2003-657404	A1	20030908 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-269533, filed on 1 Jun 1999, GRANTED, Pat. No. US 6670452 A 371 of International Ser. No. WO 1997-GB2610, filed on 25 Sep 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-20153	19960927

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 1568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 25 USPATFULL on STN
TI Compositions and methods for treatment of neoplastic disease
AB Compositions and methods for treating a tumor, neoplastic disease or infectious disease in a subject are based on superantigens in the form of polypeptides including fusion polypeptides or conjugates, homologues, and fragments, all of which induce a tumoricidal response when administered directly into tumor or an organ sheath or body cavity affected by the tumor. Nucleic acid constructs encoding the foregoing polypeptides are also used in antitumor therapy. The above agents may be administered in sustained release or controlled release vehicles at or near sites of tumors in a tumor-bearing subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:274281 USPATFULL
TITLE: Compositions and methods for treatment of neoplastic disease

INVENTOR(S): Terman, David S., Pebble Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004214783	A1	20041028
APPLICATION INFO.:	US 2003-428817	A1	20030505 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-378988P	20020508 (60)
	US 2002-389366P	20020615 (60)
	US 2002-406697P	20020828 (60)
	US 2002-406750P	20020829 (60)
	US 2002-415310P	20021001 (60)
	US 2002-415400P	20021002 (60)
	US 2003-438686P	20030109 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 20475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 25 USPATFULL on STN
TI Novel composition
AB The present invention relates to novel therapies and treatments of atherosclerotic diseases. Accordingly there is provided, methods of treating or preventing atherosclerosis by passive vaccination through administration to a patient of a fully human antibody that is capable of binding to the specific fragments of ApoCIII. Specific human monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the antibodies of the present invention in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:239240 USPATFULL
TITLE: Novel composition
INVENTOR(S): Dhaese, Patrick, Rixensart, BELGIUM
Mettens, Pascal, Rixensart, BELGIUM
Meykens, Rene, Rixensart, BELGIUM
Monteyne, Philippe, Rixensart, BELGIUM
Schiott, Torbjorn, Lund, SWEDEN
Strandberg, Leif, Lund, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004185044	A1	20040923
APPLICATION INFO.:	US 2003-387955	A1	20030715 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-EP9650	20020829

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Andrea Lockenour, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 1031

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 25 USPATFULL on STN
TI METHOD FOR MAKIN ANTIBODIES IMMUNOREATIVE WITH AN EPITOPE OF AN APOLIPOPROTEIN
AB Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as "dipsticks". The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample. The amount of lipid associated with a bound lipoprotein or the amount of apolipoprotein bound on the dipstick is quantitated using an appropriate method, for example, by staining with a lipid stain or reaction with a second labelled antibody. The intensity of the stain on the dipstick is proportional to the concentration of the lipoprotein lipid or apolipoprotein circulating in the blood and can be quantitated by comparison with standards containing known amounts of lipid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:70094 USPATFULL			
TITLE:	METHOD FOR MAKIN ANTIBODIES IMMUNOREATIVE WITH AN EPITOPE OF AN APOLIPOPROTEIN			
INVENTOR(S):	KOREN, EUGEN, SAN FRANCISCO, CA, UNITED STATES KOSCEC, MIRNA, OKLAHOMA CITY, OK, UNITED STATES			
PATENT ASSIGNEE(S):	PATREA L PABST HOLLAND AND KNIGHT LLP, ATLANTA, GA, 30309-3400 (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004053321	A1	20040318	
APPLICATION INFO.:	US 1996-765324	A1	19961224	(8)
	WO 1995-US8331		19950630	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	PATREA L. PABST, HOLLAND & KNIGHT LLP, SUITE 2000, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, N.E., ATLANTA, GA, 30309-3400			
NUMBER OF CLAIMS:	44			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2275			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 25 USPATFULL on STN
TI Compositions and methods for treatment of neoplastic disease
AB The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides, nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells,

hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are tumoricidal T cells and NKT cells devoid of inhibitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compositions and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:225302 USPATFULL			
TITLE:	Compositions and methods for treatment of neoplastic disease			
INVENTOR(S):	Terman, David S., Pebble Beach, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003157113	A1	20030821	
APPLICATION INFO.:	US 2000-751708	A1	20001228	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 1999-173371P		19991228	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	David S. Terman, P.O. Box 987, Pebble beach, CA, 93953			
NUMBER OF CLAIMS:	60			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	3 Drawing Page(s)			
LINE COUNT:	15804			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 25 USPATFULL on STN

TI Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding

AB The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:161871 USPATFULL			
TITLE:	Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding			
INVENTOR(S):	Innerarity, Thomas, Lafayette, CA, United States Boren, Jan, Gothenburg, SWEDEN			
PATENT ASSIGNEE(S):	The Regents of University of California, Oakland, CA, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6579682	B1	20030617	
APPLICATION INFO.:	US 1999-265222		19990305	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 1998-77618P		19980310	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Le, Long V.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 2243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 25 USPATFULL on STN
TI Compositions and methods for treatment of neoplastic disease
AB The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides, nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are tumoricidal T cells and NKT cells devoid of inhitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compositions and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:315069 USPATFULL
TITLE: Compositions and methods for treatment of neoplastic disease
INVENTOR(S): Terman, David S., Pebble Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177551	A1	20021128
APPLICATION INFO.:	US 2001-870759	A1	20010530 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208128P	20000531 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: David S. Terman, P.O. Box 987, Pebble Beach, CA, 93953
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 17323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 25 USPATFULL on STN
TI NON-NATURALLY OCCURRING LIPOPROTEIN PARTICLE
AB Non-naturally occurring receptor competent LDL particle comprising at least one peptide component wherein the said peptide component comprises at least a binding site for an Apo B protein receptor and at least one lipophilic substituent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:266421 USPATFULL

TITLE: NON-NATURALLY OCCURRING LIPOPROTEIN PARTICLE
INVENTOR(S): HALBERT, GAVIN WILLIAM, JORDANHILL, UNITED KINGDOM
OWENS, MOIRA DOREEN, SHAWLANDS, UNITED KINGDOM
BAILLIE, GEORGE, GALSTON, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002147304	A1	20021010	
	US 6670452	B2	20031230	
APPLICATION INFO.:	US 1999-269533	A1	19990601	(9)
	WO 1997-GB2610		19970925	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-20153	19960927

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 1249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 25 USPATFULL on STN
TI Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
AB The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein (VLDL) binding to and degradation by fibroblast or HepG2 cells. Also provided are possible applications of the synthetic peptides in lowering human plasma LDL/VLDL cholesterol levels, thus inhibiting atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:235978 USPATFULL
TITLE: Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
INVENTOR(S): Anantharamaiah, Gattadahalli M., Birmingham, AL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002128175	A1	20020912	
	US 6506880	B2	20030114	
APPLICATION INFO.:	US 2000-520698	A1	20000307	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-271066, filed on 17 Mar 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-78229P	19980317 (60)
	US 1998-78229P	19980317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gretchen A Rice, Hale and Dorr LLP, 60 State Street, Boston, MA, 02109
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 1042
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 25 USPATFULL on STN
TI ANTIBODIES TO LIPOPROTEINS AND APOLIPOPROTEINS AND METHODS OF USE THEREOF
AB Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as "dipsticks". The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample. The amount of lipid associated with a bound lipoprotein or the amount of apolipoprotein bound on the dipstick is quantitated using an appropriate method, for example, by staining with a lipid stain or reaction with a second labelled antibody. The intensity of the stain on the dipstick is proportional to the concentration of the lipoprotein lipid or apolipoprotein circulating in the blood and can be quantitated by comparison with standards containing known amounts of lipid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:185684 USPATFULL
TITLE: ANTIBODIES TO LIPOPROTEINS AND APOLIPOPROTEINS AND METHODS OF USE THEREOF
INVENTOR(S): KOREN, EUGEN, OKLAHOMA CITY, OK, UNITED STATES
KOSCEC, MIRNA, OKLAHOMA CITY, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098597	A1	20020725
APPLICATION INFO.:	US 1997-970045	A1	19971113 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-268809, filed on 30 Jun 1994, PATENTED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PATREA L. PABST, HOLLAND AND KNIGHT LLP, ONE ATLANTIC CENTER, SUITE 2000, ATLANTA, GA, 30309-3400
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
LINE COUNT: 2194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 25 USPATFULL on STN
TI Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
AB The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which

express the mutant apo-B100 proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:176371 USPATFULL
TITLE:	Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
INVENTOR(S):	Innerarity, Thomas, Lafayette, CA, United States Boren, Jan, Goteberg, Sweden

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001029027	A1	20011011
	US 7038011	B2	20060502
APPLICATION INFO.:	US 2001-822965	A1	20010329 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-265222, filed on 5 Mar 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-77618P	19980310 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Gladys H. Monroy, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Page(s)
LINE COUNT:	1993

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 25 USPATFULL on STN

TI Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding

AB The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:165587 USPATFULL
TITLE:	Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
INVENTOR(S):	Innerarity, Thomas, Lafayette, CA, United States Boren, Jan, Goteberg, Sweden

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001024797	A1	20010927
	US 6933284	B2	20050823
APPLICATION INFO.:	US 2001-823418	A1	20010329 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-265222, filed on 5 Mar 1999, PENDING

	NUMBER	DATE

PRIORITY INFORMATION:	US 1998-77618P 19980310 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Gladys H. Monroy, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Page(s)
LINE COUNT:	2035

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 25 USPATFULL on STN

TI Antibodies to lipoproteins and apolipoproteins and methods of use thereof

AB Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as "dipsticks". The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample. The amount of lipid associated with a bound lipoprotein or the amount of apolipoprotein bound on the dipstick is quantitated using an appropriate method, for example, by staining with a lipid stain or reaction with a second labelled antibody. The intensity of the stain on the dipstick is proportional to the concentration of the lipoprotein lipid or apolipoprotein circulating in the blood and can be quantitated by comparison with standards containing known amounts of lipid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:109551 USPATFULL
TITLE:	Antibodies to lipoproteins and apolipoproteins and methods of use thereof
INVENTOR(S):	Koren, Eugen, Oklahoma City, OK, United States Koscec, Mirna, Oklahoma City, OK, United States
PATENT ASSIGNEE(S):	Oklahoma Medical Research Foundation, Oklahoma City, OK, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6107045		20000822	
APPLICATION INFO.:	US 1994-268809		19940630	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Duffy, Patricia A.
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory, LLP
NUMBER OF CLAIMS:	31
EXEMPLARY CLAIM:	1
LINE COUNT:	2296

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 25 USPATFULL on STN

TI Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom

AB The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid

materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor binding the like, may be measured, to drug discovery assays. Corresponding methods of treatment and pharmaceutical compositions are disclosed that are based on an active ingredient or ingredients that demonstrates the ability to modulate the levels of all of the foregoing markers of lipid oxidation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:19198 USPATFULL
TITLE:	Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
INVENTOR(S):	Bucala, Richard J., New York, NY, United States Vlassara, Helen, Shelter Island, NY, United States Cerami, Anthony, Shelter Island, NY, United States
PATENT ASSIGNEE(S):	The Picower Institute for Medical Research, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869534		19990209
APPLICATION INFO.:	US 1993-29417		19930311 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-887279, filed on 21 May 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lambkin, Deborah C.		
LEGAL REPRESENTATIVE:	Klauber & Jackson		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	2130		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 25 USPATFULL on STN

TI Methods and materials for the diagnosis and treatment of conditions such as stroke

AB The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor binding the like, may be measured, to drug discovery assays. Corresponding methods of treatment and pharmaceutical compositions are disclosed that are based on an active ingredient or ingredients that demonstrates the ability to modulate the levels of all of the foregoing markers of lipid oxidation. A further aspect of the invention relates to the treatment of stroke and related maladies, especially to the inhibition of infarct size of stroke, and to agents and compositions that are prepared for such purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:104770 USPATFULL

TITLE: Methods and materials for the diagnosis and treatment of conditions such as stroke

INVENTOR(S): Bucala, Richard J., New York, NY, United States
Vlassara, Helen, Shelter Island, NY, United States
Cerami, Anthony, Shelter Island, NY, United States
Tracey, Kevin J., Old Greenwich, CT, United States

PATENT ASSIGNEE(S): The Picower Institute for Medical Research, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5801200		19980901
APPLICATION INFO.:	US 1995-418525		19950407 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-319747, filed on 7 Oct 1994 And a continuation-in-part of Ser. No. US 1994-236228, filed on 29 Apr 1994, now patented, Pat. No. US 5468777 which is a continuation-in-part of Ser. No. US 1992-825598, filed on 27 Jan 1992, now patented, Pat. No. US 5334617 which is a continuation-in-part of Ser. No. US 1991-805200, filed on 10 Dec 1991, now patented, Pat. No. US 5238968 which is a division of Ser. No. US 1990-481869, filed on 20 Jan 1990, now patented, Pat. No. US 5128360 which is a continuation-in-part of Ser. No. US 1988-220504, filed on 18 Jul 1988, now abandoned which is a division of Ser. No. US 1985-798032, filed on 14 Nov 1985, now patented, Pat. No. US 4758583 which is a continuation-in-part of Ser. No. US 1984-590820, filed on 19 Mar 1984, now patented, Pat. No. US 4665192 , said Ser. No. US 1994-319747, filed on 7 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-29417, filed on 11 Mar 1993 which is a continuation-in-part of Ser. No. US 1992-887279, filed on 21 May 1992, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Burn, Brian M.
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 2918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 25 USPATFULL on STN
TI DNA encoding recombinant lipoprotein antigens
AB Methods and compositions are described for determining the level of low density lipoproteins (LDL) in plasma. Native apoprotein B-100 (apo B-100) present in LDL particles is immunologically mimicked by a polypeptide of the invention. A polypeptide includes an amino acid residue sequence corresponding to a pan epitope region of the target apoprotein. A preferred polypeptide is a fusion protein that simultaneously mimics native apo B-100 and native apo A-I. Improved assay systems and methods for determining HDL and LDL levels in a body fluid sample are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:88695 USPATFULL

TITLE: DNA encoding recombinant lipoprotein antigens

INVENTOR(S): Smith, Richard S., Del Mar, CA, United States

Curtiss, Linda K., San Diego, CA, United States
Koduri, Kanaka Raju, San Diego, CA, United States
Witztum, Joseph L., San Diego, CA, United States
Young, Stephen G., Hillsborough, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, LaJolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5786206		19980728
APPLICATION INFO.:	US 1994-333577		19941031 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-959946, filed on 8 Oct 1992, now patented, Pat. No. US 5408038 which is a continuation-in-part of Ser. No. US 1992-901706, filed on 18 Jun 1992, now abandoned which is a continuation of Ser. No. US 1991-774633, filed on 9 Oct 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Lau, Kawai
LEGAL REPRESENTATIVE: Welsh & Katz, Ltd.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 10
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 3015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 25 USPATFULL on STN
TI Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom
AB The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as ME-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor binding the like, may be measured, to drug discovery assays. Corresponding methods of treatment and pharmaceutical compositions are disclosed that are based on an active ingredient or ingredients that demonstrates the ability to modulate the levels of all of the foregoing markers of lipid oxidation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:82889 USPATFULL
TITLE: Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom
INVENTOR(S): Bucala, Richard J., New York, NY, United States
Vlassara, Helen, Shelter Island, NY, United States
Cerami, Anthony, Shelter Island, NY, United States
PATENT ASSIGNEE(S): The Picower Institute For Medical Research, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780615		19980714
APPLICATION INFO.:	US 1995-486605		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-29417, filed on 11 Mar

1993 which is a continuation-in-part of Ser. No. US 1992-887279, filed on 21 May 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Lee, Howard C.
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 25 USPATFULL on STN
TI Methods and materials for the diagnosis and treatment of conditions such as stroke
AB The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor binding the like, may be measured, to drug discovery assays. Corresponding methods of treatment and pharmaceutical compositions are disclosed that are based on an active ingredient or ingredients that demonstrates the ability to modulate the levels of all of the foregoing markers of lipid oxidation. A further aspect of the invention relates to the treatment of stroke and related maladies, and to agents and compositions that are prepared for such purpose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 97:120268 USPATFULL
TITLE: Methods and materials for the diagnosis and treatment of conditions such as stroke
INVENTOR(S): Bucala, Richard J., New York, NY, United States
Vlassara, Helen, Shelter Island, NY, United States
Cerami, Anthony, Shelter Island, NY, United States
Tracey, Kevin J., Old Greenwich, CT, United States
PATENT ASSIGNEE(S): The Picowder Institute for Medical Research, Manhasset, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5700447		19971223
APPLICATION INFO.:	US 1994-319747		19941007 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-29417, filed on 11 Mar 1993 which is a continuation-in-part of Ser. No. US 1992-887279, filed on 21 May 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Burn, Brian M.
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 2319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 25 USPATFULL on STN
TI Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
AB Methods and compositions are described for determining the level of low density lipoproteins (LDL) in plasma. Native apoprotein B-100 (apo B-100) present in LDL particles is immunologically mimicked by a polypeptide of the invention. A polypeptide includes an amino acid residue sequence corresponding to a pan epitope region of the target apoprotein. A preferred polypeptide is a fusion protein that simultaneously mimics native apo B-100 and native apo A-I. Improved assay systems and methods for determining HDL and LDL levels in a body fluid sample are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 95:34283 USPATFULL
TITLE: Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
INVENTOR(S): Smith, Richard S., Del Mar, CA, United States
Curtiss, Linda K., San Diego, CA, United States
Koduri, Kanaka R., San Diego, CA, United States
Witztum, Joseph L., San Diego, CA, United States
Young, Stephen G., Hillsborough, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5408038		19950418
APPLICATION INFO.:	US 1992-959946		19921008 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-901706, filed on 18 Jun 1992, now abandoned which is a continuation of Ser. No. US 1991-774633, filed on 9 Oct 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Parr, Margaret
ASSISTANT EXAMINER: Schreiber, David
LEGAL REPRESENTATIVE: Welsh & Katz
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 2961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 25 USPATFULL on STN
TI Hybridomas and monoclonal paratopic molecules to apolipoprotein A-I
AB Hybridomas and their secreted paratopic molecules that immunoreact with apolipoprotein A-I are disclosed, as are assay methods for determining the presence and amount of apo A-I, and diagnostic systems useful in performing those determinations. Monoclonal paratopic molecules secreted by hybridomas having ATCC accession numbers HB 9200, HB 9201, HB 9202, HB 9203 and HB 9204 are utilized.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 92:53191 USPATFULL
TITLE: Hybridomas and monoclonal paratopic molecules to apolipoprotein A-I
INVENTOR(S): Curtiss, Linda K., 8926 Flanders Dr., San Diego, CA, United States 92126

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5126240		19920630

APPLICATION INFO.: US 1986-913061 19860929 (6)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine
ASSISTANT EXAMINER: Scheiner, Laurie A.
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 25 USPATFULL on STN
TI Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample
AB Methods of determining the ratio of apolipoprotein B-100 to apolipoprotein A-I using ELISA techniques in conjunction with monoclonal paratopic molecules are disclosed as are diagnostic systems useful in performing those determinations. Monoclonal paratopic molecules secreted by hybridomas having ATCC accession numbers HB 8742, HB 8746, HB 9200 and HB 9201 are utilized.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 89:36656 USPATFULL
TITLE: Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample
INVENTOR(S): Smith, Richard S., Del Mar, CA, United States
Hogle, Doreen M., San Diego, CA, United States
Curtiss, Linda K., San Diego, CA, United States
Witztum, Joseph L., San Diego, CA, United States
Young, Steven, San Diego, CA, United States
PATENT ASSIGNEE(S): Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4828986		19890509
APPLICATION INFO.:	US 1986-913140		19860929 (6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Warden, Robert J.
ASSISTANT EXAMINER: Wieder, Stephen C.
LEGAL REPRESENTATIVE: Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 25 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Non-naturally occurring lipoprotein particle.
AB Non-naturally occurring receptor competent LDL particle comprising at least one peptide component wherein the said peptide component comprises at least a binding site for an Apo B protein receptor and at least one lipophilic substituent.
ACCESSION NUMBER: 2004:80745 BIOSIS
DOCUMENT NUMBER: PREV200400082659
TITLE: Non-naturally occurring lipoprotein particle.
AUTHOR(S): Halbert, Gavin William [Inventor, Reprint Author]; Owens, Moira Doreen [Inventor]; Baillie, George [Inventor]
CORPORATE SOURCE: Jordanhill, UK

```
                    ASSIGNEE: University of Strathclyde, Glasgow, UK
PATENT INFORMATION: US 6670452 20031230
SOURCE:             Official Gazette of the United States Patent and Trademark
                    Office Patents, (Dec 30 2003) Vol. 1277, No. 5.
                    http://www.uspto.gov/web/menu/patdata.html. e-file.
                    ISSN: 0098-1133 (ISSN print).
DOCUMENT TYPE:      Patent
LANGUAGE:           English
ENTRY DATE:         Entered STN: 4 Feb 2004
                    Last Updated on STN: 4 Feb 2004


=> d his

     (FILE 'HOME' ENTERED AT 10:23:06 ON 02 AUG 2006)

     FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS' ENTERED AT 10:38:25 ON 02 AUG
     2006
L1          1862 S LDL PARTICLE
L2          9562 S APO B
L3           496 S L2 AND (BINDING SITE)
L4            25 S L3 AND L1

=> s (receptor competent low density lipoprotein particle) and (peptide component)
L5             1 (RECEPTOR COMPETENT LOW DENSITY LIPOPROTEIN PARTICLE) AND (PEPTI
                 DE COMPONENT)

=> d 15 ti abs ibib tot

L5   ANSWER 1 OF 1  USPATFULL on STN
TI     Non-naturally occurring lipoprotein particle
AB     Non-naturally occurring lipoprotein particles, process for preparing
       such particles and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2004:299861  USPATFULL
TITLE:                   Non-naturally occurring lipoprotein particle
INVENTOR(S):             Halbert, Gavin William, Jordanhill, UNITED KINGDOM
                         Owens, Moira Doreen, Basel, SWITZERLAND
                         Baillie, George, Lochwinnoch, UNITED KINGDOM
PATENT ASSIGNEE(S):      University of Strathclyde (non-U.S. corporation)

                              NUMBER        KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 2004235730      A1   20041125
APPLICATION INFO.:       US 2003-657404     A1   20030908  (10)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 1999-269533, filed
                         on 1 Jun 1999, GRANTED, Pat. No. US 6670452 A 371 of
                         International Ser. No. WO 1997-GB2610, filed on 25 Sep
                         1997, UNKNOWN

                                NUMBER         DATE
                         ----------------- --------
PRIORITY INFORMATION:    GB 1996-20153      19960927
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH
                         TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
NUMBER OF CLAIMS:        25
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      18 Drawing Page(s)
LINE COUNT:              1568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
=> d his

     (FILE 'HOME' ENTERED AT 10:23:06 ON 02 AUG 2006)

     FILE 'MEDLINE, USPATFULL, BIOSIS, WPIDS' ENTERED AT 10:38:25 ON 02 AUG
     2006
L1          1862 S LDL PARTICLE
L2          9562 S APO B
L3           496 S L2 AND (BINDING SITE)
L4            25 S L3 AND L1
L5             1 S (RECEPTOR COMPETENT LOW DENSITY LIPOPROTEIN PARTICLE) AND (PE

=> s l1 and (lipophilic substituent)
L6             3 L1 AND (LIPOPHILIC SUBSTITUENT)

=> d l6 ti abs ibib tot

L6   ANSWER 1 OF 3  USPATFULL on STN
TI     Non-naturally occurring lipoprotein particle
AB     Non-naturally occurring lipoprotein particles, process for preparing
       such particles and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2004:299861  USPATFULL
TITLE:                    Non-naturally occurring lipoprotein particle
INVENTOR(S):              Halbert, Gavin William, Jordanhill, UNITED KINGDOM
                          Owens, Moira Doreen, Basel, SWITZERLAND
                          Baillie, George, Lochwinnoch, UNITED KINGDOM
PATENT ASSIGNEE(S):       University of Strathclyde (non-U.S. corporation)

                               NUMBER        KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2004235730      A1   20041125
APPLICATION INFO.:        US 2003-657404     A1   20030908  (10)
RELATED APPLN. INFO.:     Continuation-in-part of Ser. No. US 1999-269533, filed
                          on 1 Jun 1999, GRANTED, Pat. No. US 6670452 A 371 of
                          International Ser. No. WO 1997-GB2610, filed on 25 Sep
                          1997, UNKNOWN

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     GB 1996-20153      19960927
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH
                          TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
NUMBER OF CLAIMS:         25
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       18 Drawing Page(s)
LINE COUNT:               1568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6   ANSWER 2 OF 3  USPATFULL on STN
TI     NON-NATURALLY OCCURRING LIPOPROTEIN PARTICLE
AB     Non-naturally occurring receptor competent LDL
       particle comprising at least one peptide component wherein the
       said peptide component comprises at least a binding site for an Apo B
       protein receptor and at least one lipophilic
       substituent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

ACCESSION NUMBER: 2002:266421 USPATFULL
TITLE: NON-NATURALLY OCCURRING LIPOPROTEIN PARTICLE
INVENTOR(S): HALBERT, GAVIN WILLIAM, JORDANHILL, UNITED KINGDOM
OWENS, MOIRA DOREEN, SHAWLANDS, UNITED KINGDOM
BAILLIE, GEORGE, GALSTON, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002147304	A1	20021010	
	US 6670452	B2	20031230	
APPLICATION INFO.:	US 1999-269533	A1	19990601	(9)
	WO 1997-GB2610		19970925	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-20153	19960927

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 1249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 3 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Non-naturally occurring lipoprotein particle.
AB Non-naturally occurring receptor competent LDL particle comprising at least one peptide component wherein the said peptide component comprises at least a binding site for an Apo B protein receptor and at least one lipophilic substituent.
ACCESSION NUMBER: 2004:80745 BIOSIS
DOCUMENT NUMBER: PREV200400082659
TITLE: Non-naturally occurring lipoprotein particle.
AUTHOR(S): Halbert, Gavin William [Inventor, Reprint Author]; Owens, Moira Doreen [Inventor]; Baillie, George [Inventor]
CORPORATE SOURCE: Jordanhill, UK
ASSIGNEE: University of Strathclyde, Glasgow, UK
PATENT INFORMATION: US 6670452 20031230
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Dec 30 2003) Vol. 1277, No. 5. http://www.uspto.gov/web/menu/patdata.html. e-file. ISSN: 0098-1133 (ISSN print).
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 4 Feb 2004
Last Updated on STN: 4 Feb 2004